Search

Displaying results 2671 - 2680 of 10000 in total
  1. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. … Pharmacologic estrogen products are available in a variety of formats.

  2. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  3. Drug

    Dinalbuphine sebacate

    go.drugbank.com/drugs/DB15341
    Investigational

    Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

    Products: NALDEBAIN® EXTENDED RELEASE INJECTION 75MG/ML
  4. Drug

    Pranoprofen

    go.drugbank.com/drugs/DB13514
    Investigational

    Pranoprofen is an anti-inflammatory agent.

    Products: OFTALAR STERIL GOZ DAMLASI 5 ML
  5. Drug

    gamma-Aminobutyric acid

    go.drugbank.com/drugs/DB02530
    ApprovedInvestigational

    The most common inhibitory neurotransmitter in the central nervous system.

    Mixtures: Theraproxen-500, Theraprofen-800Synonyms: γ-amino-n-butyric acid
  6. Drug

    Diloxanide furoate

    go.drugbank.com/drugs/DB14638
    ApprovedInvestigational

    Synonyms: 2,2-dichloroacetamido-4-n-methylphenyl 2-furoate, 4-(n-methyl-2,2-dichloroacetamido)phenyl 2-furoate
  7. Drug

    GTI 2040

    go.drugbank.com/drugs/DB05801
    Investigational

    GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

  8. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    efficacy of a 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes.

  9. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.

    Products: Navane Cap 2mg
  10. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.[L12162]